Reducing stroke rates using left atrial appendage occlusion

Submission date	Recruitment status No longer recruiting	Prospectively registered		
09/03/2016		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
10/03/2016	Completed	[X] Results		
Last Edited 07/06/2022	Condition category Circulatory System	[] Individual participant data		

Plain English summary of protocol

Background and study aims

Atrial fibrillation (AF) is a common heart condition, affecting millions of people worldwide. The heart consists of two upper chambers (atria) and two lower chambers (ventricles). Inside the right atrium, a cluster of cells (sinus node) are responsible for firing electrical signals into the heart muscle causing the heart to beat regularly (sinus rhythm). When a person is suffering from AF, the normal signals from the sinus node do not work properly, causing other parts of the atria to fire chaotically. These uncoordinated signals cause the heart to beat irregularly and often very fast (arrhythmia). People suffering from AF have a much higher risk of developing other problems, such as stroke. Prevention of stroke in people with AF is usually achieved using blood thinning medications such as colchicine however this is not always effective and there is a risk of serious bleeding. The left atrial appendage is a small structure in the muscle wall of the left atrium and is thought to be the most common source of blood clots causing stroke in patients with AF. Left atrial appendage closure (LAAC) is a treatment strategy which has been an area of interest in the field of stroke prevention. Blocking off (occluding) this structure during surgery using a suture (stitch) or surgical stapler, could be an effective method of stroke prevention in these patients, removing the need to take blood thinners. The aim of this study is to find out whether left atrial appendage occlusion can help to lower the occurrence of stroke in AF patients.

Who can participate?

Adults with AF who are having heart surgery involving a cardiopulmonary bypass.

What does the study involve?

Participants are randomly allocated to one of two groups. For those in the first group, during their surgery, the surgeon will block off (occlude) the left atrial appendage using a suture (stitch) and/or surgical stapler. For those in the second group, the left atrial appendage is not closed during surgery. Participants in both groups are followed up in order to find out which group has the higher occurrence of stroke.

What are the possible benefits and risks of participating? Not provided at time of registration. Where is the study run from? Hammersmith Hospital (UK)

When is the study starting and how long is it expected to run for? November 2015 to December 2017

Who is funding the study? Canadian Institutes for Health Research (UK)

Who is the main contact?

1. Mr Sajiram Sarvananthan (public) s.sajiram@imperial.ac.uk

2. Mr Prakash Punjabi (scientific) p.punjabi@imperial.ac.uk

Contact information

Type(s)

Public

Contact name

Mr Sajiram Sarvananthan

Contact details

Imperial College Healthcare NHS Trust Hammersmith Hospital Du Cane Road London United Kingdom W12 0HS +44 7949 554467 s.sajiram@imperial.ac.uk

Type(s)

Scientific

Contact name

Mr Prakash Punjabi

Contact details

Hammersmith Hospital
Department Of Cardiothoracic Surgery
Du Cane Road
London
United Kingdom
W12 0HS
+44 208 383 2026
p.punjabi@imperial.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT01561651

Secondary identifying numbers

19759

Study information

Scientific Title

Left Atrial Appendage Occlusion Study III (LAAOS III)

Study objectives

The aim of this study is to examine the impact of left atrial appendage occlusion on the incidence of stroke or systemic arterial embolism in patients with atrial fibrillation undergoing cardiac surgery over the duration of follow -up.

Ethics approval required

Old ethics approval format

Ethics approval(s)

15/LO/0769

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiac Surgery

Interventions

Participants are randomly allocated to one of two groups.

Intervention group: Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.

Control group: Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure.

Intervention Type

Other

Phase

Phase III

Primary outcome measure

First occurrence of stroke or systemic arterial embolism over the duration of follow-up.

Secondary outcome measures

Not provided at time of registration

Overall study start date

30/11/2015

Completion date

30/04/2021

Eligibility

Key inclusion criteria

- 1. Aged 18 years or above
- 2. Undergoing a clinically indicated cardiac surgical procedure with the use of cardiopulmonary bypass
- 3. A documented history of atrial fibrillation or atrial flutter
- 4. CHA2DS2--VASc score ≥ 2
- 5. Written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 4700; UK Sample Size: 200

Total final enrolment

4811

Key exclusion criteria

- 1. Patients undergoing any of the following procedures:
- 1.1. Off--pump cardiac surgery
- 1.2. Heart transplant
- 1.3. Complex congenital heart surgery
- 1.4. Sole indication for surgery is ventricular assist device insertion
- 1.5. Previous cardiac surgery (re-operation)
- 1.6. Mechanical valve implantation
- 2. Patients who have had a previous placement of a percutaneous LAA closure device

Date of first enrolment

30/11/2015

Date of final enrolment

04/09/2018

Locations

Countries of recruitment Argentina

Australia

Austria

Belgium

Brazil

Canada

China

Colombia

Czech Republic

Egypt

England

Germany

Greece

Hong Kong

India



Study participating centre
Hammersmith Hospital
Imperial College Healthcare NHS Trust
Du Cane Road
London
United Kingdom
W12 0HS

Sponsor information

Organisation

Iran

Ireland

Imperial College Healthcare NHS Trust

Sponsor details

Hammersmith Hospital Du Cane Road London England United Kingdom W12 0HS

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/056ffv270

Funder(s)

Funder type

Government

Funder Name

Canadian Institutes of Health Research

Alternative Name(s)

Instituts de Recherche en Santé du Canada, Canadian Institutes of Health Research (CIHR), CIHR_IRSC, Canadian Institutes of Health Research | Ottawa ON, CIHR, IRSC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Canada

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

15/05/2021

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		03/06/2021	07/06/2022	Yes	No
HRA research summary			28/06/2023	No	No